Savin R C
Department of Dermatology, Yale University School of Medicine, New Haven, CT.
J Am Acad Dermatol. 1990 Oct;23(4 Pt 2):807-9. doi: 10.1016/0190-9622(90)70294-r.
The safety and effectiveness of oral terbinafine, 125 mg twice daily, and griseofulvin, 250 mg twice daily, in patients with moccasin-type tinea pedis were examined in a double-blind randomized trial. At the end of the 6-week treatment period, both a clinical and mycologic cure or a mycologic cure with minimal signs of infection was noted in 12 (75%) of the 16 terbinafine-treated patients compared with only 3 (27%) of the 12 patients treated with griseofulvin. The overall response rate 2 weeks after the completion of treatment was 88% in the terbinafine-treated group and 45% in the griseofulvin-treated group. When contacted again 6 to 15 months after completion of the study, 94% of the terbinafine-treated patients reported sustained clearing of tinea pedis, and 88% of those with nail involvement at the time of treatment reported improvement. In contrast, tinea pedis remained cured in only 30% of the patients who had received griseofulvin, and onychomycosis improved in only 14%.
在一项双盲随机试验中，对口服特比萘芬（每日两次，每次125毫克）和灰黄霉素（每日两次，每次250毫克）治疗拖鞋型足癣患者的安全性和有效性进行了研究。在为期6周的治疗期结束时，16例接受特比萘芬治疗的患者中有12例（75%）实现了临床和真菌学治愈或真菌学治愈且感染迹象轻微，而在12例接受灰黄霉素治疗的患者中只有3例（27%）达到此效果。治疗结束2周后的总体缓解率在特比萘芬治疗组为88%，在灰黄霉素治疗组为45%。在研究结束6至15个月后再次联系时，94%接受特比萘芬治疗的患者报告足癣持续消退，88%在治疗时伴有指甲受累的患者报告病情改善。相比之下，接受灰黄霉素治疗的患者中只有30%足癣仍保持治愈状态，甲癣改善的患者仅为14%。
